Eduard A van de Graaf
Overview
Explore the profile of Eduard A van de Graaf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Willemse J, Wener R, Feroldi F, Vaselli M, Kwakkel-Van Erp J, van de Graaf E, et al.
Biomed Opt Express
. 2021 Dec;
12(11):6796-6813.
PMID: 34858681
A non-invasive diagnostic tool to assess remodeling of the lung airways caused by disease is currently missing in the clinic. Measuring key features such as airway smooth muscle (ASM) thickness...
2.
Wessels-Bakker M, van de Graaf E, Kwakkel-Van Erp J, Heijerman H, Cahn W, Schappin R
J Clin Nurs
. 2021 Jul;
31(5-6):716-725.
PMID: 34216066
Aims And Objectives: To explore the prevalence of psychological distress such as anxiety, depression and post-traumatic stress disorder and its associations with medication adherence in lung transplant patients. Background: Psychological...
3.
Kardol-Hoefnagel T, Budding K, van de Graaf E, van Setten J, van Rossum O, Oudijk E, et al.
Front Immunol
. 2019 Oct;
10:2245.
PMID: 31616421
Development of chronic rejection is still a severe problem and causes high mortality rates after lung transplantation (LTx). Complement activation is important in the development of acute rejection (AR) and...
4.
Berkers G, van Mourik P, Vonk A, Kruisselbrink E, Dekkers J, de Winter-de Groot K, et al.
Cell Rep
. 2019 Feb;
26(7):1701-1708.e3.
PMID: 30759382
In vitro drug tests using patient-derived stem cell cultures offer opportunities to individually select efficacious treatments. Here, we provide a study that demonstrates that in vitro drug responses in rectal...
5.
Budding K, van Setten J, van de Graaf E, van Rossum O, Kardol-Hoefnagel T, Kwakkel-Van Erp J, et al.
Front Immunol
. 2019 Feb;
9:3105.
PMID: 30705675
Obstructive chronic lung allograft dysfunction (BOS) is the major limiting factor for lung transplantation (LTx) outcome. is described as the hallmark autoimmunity gene, and one specific single nucleotide polymorphism (SNP),...
6.
Budding K, van Setten J, van de Graaf E, van Rossum O, Kardol-Hoefnagel T, Oudijk E, et al.
Front Immunol
. 2017 Sep;
8:1109.
PMID: 28932229
Lung transplantation (LTx) outcome is hampered by development of chronic rejection, often manifested as the bronchiolitis obliterans syndrome (BOS). Low serum levels of thymus and activation-regulated chemokine (TARC/CCL17), a chemoattractant,...
7.
Budding K, van de Graaf E, Kardol-Hoefnagel T, Oudijk E, Kwakkel-Van Erp J, Hack C, et al.
Front Immunol
. 2017 Apr;
8:322.
PMID: 28377770
Antibodies against HLA and non-HLA are associated with transplantation outcome. Recently, pretransplant serum IgG antibody levels against apoptotic cells were found to correlate with kidney allograft loss. We investigated the...
8.
Vijftigschild L, Berkers G, Dekkers J, Zomer-van Ommen D, Matthes E, Kruisselbrink E, et al.
Eur Respir J
. 2016 Jul;
48(3):768-79.
PMID: 27471203
We hypothesized that people with cystic fibrosis (CF) who express CFTR (cystic fibrosis transmembrane conductance regulator) gene mutations associated with residual function may benefit from G-protein coupled receptor (GPCR)-targeting drugs...
9.
Dekkers J, Berkers G, Kruisselbrink E, Vonk A, De Jonge H, Janssens H, et al.
Sci Transl Med
. 2016 Jun;
8(344):344ra84.
PMID: 27334259
Identifying subjects with cystic fibrosis (CF) who may benefit from cystic fibrosis transmembrane conductance regulator (CFTR)-modulating drugs is time-consuming, costly, and especially challenging for individuals with rare uncharacterized CFTR mutations....
10.
Budding K, van de Graaf E, Kardol-Hoefnagel T, Kwakkel-Van Erp J, Luijk B, Oudijk E, et al.
Sci Rep
. 2016 May;
6:26274.
PMID: 27215188
CD59 is a complement regulatory protein that inhibits membrane attack complex formation. A soluble form of CD59 (sCD59) is present in various body fluids and is associated with cellular damage...